Trial Profile

A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CM 4612 (Primary)
Indications Autistic disorder
Focus Registrational; Therapeutic Use
Acronyms Blum Study
Sponsors Curemark

Most Recent Events

06 May 2019 Results published in the Media Release
06 May 2019 According to a Curemark media release, data from the study were presented at the International Society of Autism Research (INSAR) Annual Meeting 2019. The presentation focused on data from the preschool population included in the study.
21 Mar 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com